SCHEMBL30236154

SCHEMBL30236154

CC1=CC[C@H]2C(C)(C)CCC[C@]2(C)[C@H]1CCO

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DUSP3 P51452 11/20 0.56
CDC25A P30304 9/20 0.54
PTPN1 P18031 6/20 0.50
MAPKAPK2 P49137 1/20 0.47
ATP1A1 P05023 1/20 0.45
ATP1B1 P05026 1/20 0.45
ATP1A3 P13637 1/20 0.45
ATP1B2 P14415 1/20 0.45
ATP1A2 P50993 1/20 0.45
ATP1B3 P54709 1/20 0.45
FXYD2 P54710 1/20 0.45
ATP1A4 Q13733 1/20 0.45
PLA2G2A P14555 1/20 0.44
CHRNB2 P17787 3/20 0.43
CHRNB4 P30926 3/20 0.43
CHRNA3 P32297 3/20 0.43
CHRNA4 P43681 3/20 0.43
TRPA1 O75762 1/20 0.43
CHRNA7 P36544 2/20 0.41
UGT2B7 P16662 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13455165 1.00 DUSP3 (0.56) DUSP3CDC25APTPN1MAPKAPK2ATP1A1
SCHEMBL19214454 1.00 DUSP3 (0.56) DUSP3CDC25APTPN1MAPKAPK2ATP1A1
SCHEMBL2921250 1.00 DUSP3 (0.56) DUSP3CDC25APTPN1MAPKAPK2ATP1A1
SCHEMBL2921247 1.00 DUSP3 (0.56) DUSP3CDC25APTPN1MAPKAPK2ATP1A1
SCHEMBL15886618 0.88 DUSP3 (0.58) DUSP3CDC25APTPN1MAPKAPK2ATP1A1
SCHEMBL2982726 0.88 DUSP3 (0.58) DUSP3CDC25APTPN1MAPKAPK2ATP1A1
SCHEMBL6511122 0.88 DUSP3 (0.58) DUSP3CDC25APTPN1MAPKAPK2ATP1A1
SCHEMBL4192630 0.83 ATP1A1 (0.54) DUSP3CDC25APTPN1MAPKAPK2ATP1A1
SCHEMBL4192628 0.83 ATP1A1 (0.54) DUSP3CDC25APTPN1MAPKAPK2ATP1A1
SCHEMBL3121878 0.82 DUSP3 (0.51) DUSP3CDC25APTPN1MAPKAPK2ATP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4658642-A1 PROCESS FOR PREPARING A OXACYLOPENTANE DERIVATIVE Firmenich SA (CH) 2025-12-10 EP disclosed
US-20240327367-A1 PROCESS FOR PREPARING A OXACYLOHEXANE OR OXACYLOPENTANE DERIVATIVE FIRMENICH & CIE (CH) 2024-10-03 US disclosed
WO-2024160930-A1 PROCESS FOR PREPARING A OXACYLOPENTANE DERIVATIVE FIRMENICH SA (CH) 2024-08-08 WO disclosed
EP-4377301-A2 PROCESS FOR PREPARING A OXACYLOHEXANE OR OXACYLOPENTANE DERIVATIVE Firmenich SA (CH) 2024-06-05 EP disclosed
WO-2023006910-A2 PROCESS FOR PREPARING A OXACYLOHEXANE OR OXACYLOPENTANE DERIVATIVE FIRMENICH SA (CH) 2023-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327367-A1 PROCESS FOR PREPARING A OXACYLOHEXANE OR OXACYLOPENTANE DERIVATIVE OSTC, CYP51A1, OXER1 DUSP3 4193/4885CDC25A 902/4885PTPN1 3846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.